ASCO GU 2021: Discussant: Enfortumab Vedotin (EV) in Previously Treated Urothelial Cancer – Results of EV-301 & EV-201 Cohort 2

(UroToday.com) She first reviewed the results of EV-301 (Abstract 393) which provided level 1 evidence of overall survival benefit with EV compared to single-agent chemotherapy in patients who progressed on platinum chemotherapy and immune checkpoint blockade. The trial schema and relevant overall survival data are re-shown below. EV also demonstrated a progression-free survival benefit and improved […]

Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data from two prospective trials (NCT03368547 and NCT04050215), we explored predictors of overall upstaging (nodal and metastatic) by PSMA PET/CT among patients with cN0M0 National Comprehensive […]

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Radiology “Write This Down” – What Do Nonradiologists Need to Know

(UroToday.com) In this presentation, Dr. Theodora Potretzke discussed several core messages surrounding the use of contrast with imaging for renal cell carcinoma (RCC) patients. Her major points are summarized as: (1) the risk of contrast-induced acute kidney injury from IV iodinated contrast is lower than previously thought, (2) contrast-enhanced MRI using group 2 gadolinium-based contrast agents […]

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Quality of Life Corner

(UroToday.com) In this presentation, Dr. Jodi Maranchie discussed the critical role of considering quality of life in treatment decisions for the management of renal cell carcinoma. She used multiple case examples to illustrate her points, all while emphasizing that quality of life assessment is challenging as it is a subjective concept influenced by core values and […]

ASCO GU 2021: Progress and Promise in Treatment Personalization for Advanced Prostate Cancer – Lighting the Way: Lutetium in the Treatment Paradigm

(UroToday.com) In this presentation, Dr. Mike Sathekge summarized the potential applications of lutetium in prostate cancer. Imaging is helpful for multiple reasons in prostate cancer, including helping with staging, detection of recurrence, prognostication, response monitoring, and may be helpful in therapeutic strategies and characterizing the heterogeneity of the disease.

ASCO GU 2021: An Exploratory Gene-by-Gene Analysis of Patients with mCRPC Treated with Olaparib in the PROfound Trial

(UroToday.com) Published in 2020, the Phase 3 PROfound trial (NCT02987543) was a phase III randomized controlled trial of olaparib versus physician’s choice of enzalutamide or abiraterone in men with metastatic castration resistant prostate cancer (mCRPC) with alterations in at least one of 15 homologous recombination repair genes who had disease progression on next-generation hormonal agent.1,2 The trial […]

X